Anogen is the leader among biopharmaceutical product manufacturers. Our mission is dedicated to supply the best quality of antibodies and ELISA Kits worldwide.
Tiziana Life Sciences has reported early Phase 2 PET imaging results for intranasal foralumab, a fully human anti-CD3 monoclonal antibody being studied in patients with Multiple System Atrophy (MSA
Read the full article: https://t.co/PuKLaLK8wU
#Anogen#MultipleSystemAtrophy
Tiziana Life Sciences recently reported positive preclinical findings for intranasal foralumab, a fully human anti-CD3 monoclonal antibody being developed to modulate neuroinflammation.
https://t.co/eRk9LmtU6z
#Neuroscience#AntiCD3#MonoclonalAntibody#Neuroinflammation
Recent 2026 updates are reinforcing tau as one of the most closely watched therapeutic targets in Alzheimer’s disease — but the field is moving beyond traditional anti-tau antibodies alone.
https://t.co/r7R0TfZPbU
#AlzheimersDisease#Tau#Neuroscience#Biotechnology#Anogen
A 2026 review published in Antibodies highlights that anti-TNF-α monoclonal antibodies used in inflammatory bowel disease (IBD) may work through multiple mechanisms beyond simply neutralizing soluble TNF-α.
Read the full article: https://t.co/1QRHVhitWf
#TNFAlpha#Anogen
A 2026 review in Antibody Therapeutics examines how monoclonal antibodies have transformed the treatment of Crohn’s disease by targeting specific inflammatory pathways.
Read the full article on PubMed: https://t.co/XwAXjGUFOs
#CrohnsDisease#MonoclonalAntibodies
A recent review published in Frontiers in Pharmacology highlights the growing importance of the interleukin-17 (IL-17) signaling pathway in chronic inflammation, autoimmune disorders, and cancer.
🔗 Read the full review: https://t.co/SnLWShO0fm
#IL17#Cytokines#Inflammation
The global TNF-α inhibitors market is projected to grow from $43.83 billion in 2025 to $44.95 billion in 2026, with further growth expected to reach $50.58 billion by 2030.
📖 Read more: https://t.co/HdQktzJBzL
#Anogen#TNFalpha#TNFInhibitors#Biologics#AutoimmuneDisease
A recent review published in Antibodies explores the multiple mechanisms through which anti-TNF-α antibodies may help control inflammation in inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.
📖 Read the full review:
https://t.co/7CvuLofaiq
Tiziana Life Sciences has reported PET imaging results from a third MSA patient treated with intranasal foralumab, showing reductions in neuroinflammatory activity in key brain regions affected by the disease.
Read the full article: https://t.co/0DYkKa9YNB
#Anogen
As Alzheimer's research continues to evolve, the spotlight at AAIC 2026 is shifting beyond amyloid to tau-targeted therapies, signaling an exciting new chapter in the search for disease-modifying treatments.
Read the full article: https://t.co/fxlzXanJzq
#Anogen#Alzheimer
Emerging preclinical research from Tiziana Life Sciences highlights the therapeutic potential of intranasal anti-CD3 (foralumab) as a novel approach to addressing age-related cognitive decline by targeting neuroinflammation.
Read the full article: https://t.co/eRk9Lmtmh1
Alzheimer's research continues to evolve, with advances in diagnosis, treatment, and disease monitoring bringing new hope for patients and families.
Read the full article here: https://t.co/VxWUdcRb3S
#Anogen#Alzheimers#Neuroscience#Biomarkers#MonoclonalAntibody
📈 The Anti-TNF-α monoclonal antibody market continues to demonstrate strong growth potential, driven by the increasing prevalence of autoimmune and inflammatory diseases worldwide.
Read the full article: https://t.co/lWBx3FxKmD
#Anogen#TNFalpha#Immunology#MonoclonalAntibody